Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma.

Ann Transl Med · 2021 · PMC7944271 · PMID 33708966

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

marginal significanceP=0.052so close (0.05 < p ≤ 0.1)

The ORRs of patients who received pembrolizumab treatment as first-line, second-line, and third-line therapy were 42.9% (3/7), 25.0% (4/16), and 0% (0/13), respectively, which showed marginal significance (P=0.052).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.